Annual analysis shows a new crop of biotech assets with ballooning valuations and no major partners.
Analysis of me-too drug approvals over time shows trends across therapy areas.
Bristol-Myers Squibb has come out on top of an analysis of efficiency in big pharma. Being in immuno-oncology might have helped – but so might aggressive job cuts.
Nine IPOs have got away so far this year, and one of them is very big indeed.
If the US drugs regulator picks up the pace in the second half of the year, 2018 could be a bumper year for novel medicine approvals.